Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Having witnessed a 90%-plus stock price slide during recent years, Sage Therapeutics’ leadership must decide whether now is the right time to accept a buyout offer. Biogen has offered to ...